title: Radiation therapy for primary vaginal carcinoma.
abstract: Brachytherapy plays a significant role in the management of cervical cancer, but the clinical significance of brachytherapy in the management of vaginal cancer remains to be defined. Thus, a single institutional experience in the treatment of primary invasive vaginal carcinoma was reviewed to define the role of brachytherapy. We retrospectively reviewed the charts of 36 patients with primary vaginal carcinoma who received definitive radiotherapy between 1992 and 2010. The treatment modalities included high-dose-rate intracavitary brachytherapy alone (HDR-ICBT; two patients), external beam radiation therapy alone (EBRT; 14 patients), a combination of EBRT and HDR-ICBT (10 patients), or high-dose-rate interstitial brachytherapy (HDR-ISBT; 10 patients). The median follow-up was 35.2 months. The 2-year local control rate (LCR), disease-free survival (DFS), and overall survival (OS) were 68.8%, 55.3% and 73.9%, respectively. The 2-year LCR for Stage I, II, III and IV was 100%, 87.5%, 51.5% and 0%, respectively (P = 0.007). In subgroup analysis consisting only of T2-T3 disease, the use of HDR-ISBT showed marginal significance for favorable 5-year LCR (88.9% vs 46.9%, P = 0.064). One patient each developed Grade 2 proctitis, Grade 2 cystitis, and a vaginal ulcer. We conclude that brachytherapy can play a central role in radiation therapy for primary vaginal cancer. Combining EBRT and HDR-ISBT for T2-T3 disease resulted in good local control.
authors.affiliation: Department of Radiation Oncology, National Cancer Center Hospital, 5-1-1, Tsukiji Chuo-ku, Tokyo 104-0045, Japan.
authors.forename: N
authors.initials: N
authors.lastname: Murakami
authors.forename: T
authors.initials: T
authors.lastname: Kasamatsu
authors.forename: M
authors.initials: M
authors.lastname: Sumi
authors.forename: R
authors.initials: R
authors.lastname: Yoshimura
authors.forename: K
authors.initials: K
authors.lastname: Takahashi
authors.forename: K
authors.initials: K
authors.lastname: Inaba
authors.forename: M
authors.initials: M
authors.lastname: Morota
authors.forename: H
authors.initials: H
authors.lastname: Mayahara
authors.forename: Y
authors.initials: Y
authors.lastname: Ito
authors.forename: J
authors.initials: J
authors.lastname: Itami
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001918:Brachytherapy / Q000401:mortality*; D003131:Combined Modality Therapy / Q000401:mortality; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007564:Japan / Q000453:epidemiology; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000401:mortality* / Q000517:prevention & control*; D015995:Prevalence; D020266:Radiotherapy, Conformal / Q000401:mortality*; D012189:Retrospective Studies; D012307:Risk Factors; D015996:Survival Rate; D016896:Treatment Outcome; D014625:Vaginal Neoplasms / Q000175:diagnosis / Q000401:mortality* / Q000532:radiotherapy*
keywords: high-dose-rate brachytherapy; interstitial brachytherapy; intracavitary brachytherapy; primary vaginal cancer; radiation therapy
references.citation: Strahlenther Onkol. 2009 Mar;185(3):184-9
references.pmid: 19330296
references.citation: Cancer. 1985 Feb 15;55(4):892-7
references.pmid: 3967181
references.citation: Gynecol Oncol. 2002 Feb;84(2):263-70
references.pmid: 11812085
references.citation: Int J Clin Oncol. 2013 Apr;18(2):314-20
references.pmid: 22310898
references.citation: Strahlenther Onkol. 2006 Mar;182(3):142-8
references.pmid: 16520908
references.citation: Int J Radiat Oncol Biol Phys. 2005 May 1;62(1):138-47
references.pmid: 15850914
references.citation: Int J Radiat Oncol Biol Phys. 1993 Feb 15;25(3):413-8
references.pmid: 8436518
references.citation: Cancer. 2005 Jan 1;103(1):92-101
references.pmid: 15540233
references.citation: Brachytherapy. 2012 Jan-Feb;11(1):68-75
references.pmid: 22265440
references.citation: Int J Radiat Oncol Biol Phys. 1996 Jul 15;35(5):891-905
references.pmid: 8751398
references.citation: Gynecol Oncol. 1982 Oct;14(2):154-63
references.pmid: 7129211
references.citation: Int J Gynaecol Obstet. 1999 Jun;65(3):243-9
references.pmid: 10428343
references.citation: Strahlenther Onkol. 2003 Nov;179(11):737-41
references.pmid: 14605742
references.citation: Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):e49-56
references.pmid: 21470794
references.citation: BMJ. 2004 May 1;328(7447):1073
references.pmid: 15117797